XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) saw a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 9,750 shares, a decline of 49.3% from the May 14th total of 19,218 shares. Currently, 0.6% of the shares of the company are sold short. Based on an average daily volume of 26,934 shares, the short-interest ratio is currently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

XTL Biopharmaceuticals Trading Down 9.0%

XTLB traded down $0.21 on Friday, reaching $2.13. The stock had a trading volume of 8,563 shares, compared to its average volume of 20,448. XTL Biopharmaceuticals has a 12-month low of $2.01 and a 12-month high of $10.28. The business’s 50-day moving average price is $2.54 and its two-hundred day moving average price is $4.48. The company has a market cap of $4.69 million, a P/E ratio of -3.33 and a beta of 1.48.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.